Top Abstract Purchase Related
Home
>
Node
>
Subnode

L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment

Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F.

Acta Neurologica Belgica 75(1): 5-10

1975

ISSN/ISBN: 0300-9009
PMID: 1202895
Document Number: 85027
Sixty-four all-night sleep polygraphic recordings have been carried out in patients affected by Parkinson's syndrome, before and after treatment with an association of l-dopa plus a peripheral dopa-decarboxylase inhibitor. Without any drug, parkinsonian patients showed sleep disruption with frequent awakenings, reduction of total sleeping time and lessening of REM stage rather than slow sleep. Treatment with l-dopa plus inhibitor appeared to be able to restore good night sleep organization with a noteworthy increase in the REM stage.

Document emailed within 1 workday
Secure & encrypted payments

Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Christiani, K.; Möller, W.D. 1973: Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor Münchener Medizinische Wochenschrift 115(16): 711-713
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Fischer, P.A.; Schneider, E.; Jacobi, P.; Maxion, H. 1973: Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor Die Medizinische Welt 24(45): 1742-1746
Pontiroli, A.E.; Castegnaro, E.; Vettaro, M.P.; Viberti, G.C.; Pozza, G. 1977: Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine Acta Endocrinologica 84(1): 36-44
Geissbuhler, F.; Eisenring, J.J.; Friedli, P.; Bartholini, G.; Tissot, R. 1972: Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects L'Encephale 61(2): 127-148
Wajsbort, J.; Hemli, J.A.; Alfandary, I.; Yahel, M.; Siegfried, J. 1971: Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association Wiener Medizinische Wochenschrift 121(42): 741-745
Blair, M.L.; Reid, I.A.; Ganong, W.F. 1977: Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs Journal of Pharmacology and Experimental Therapeutics 202(1): 209-215
Eisenlohr, J.J.; Gehlen, W. 1975: Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor) Der Nervenarzt 46(3): 128-135
Puca, F.M.; Bricolo, A.; Turella, G. 1972: Effects of L-dopa or amantadine treatment on the spindles of sleep in Parkinson's syndromes Revue Neurologique (Paris) 127(2): 313
Rabadeau Dumas, J.L.; Rondot, P.; Cardon, P. 1977: Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor Therapie 32(2): 161-172
Stammler, A.; Vielhaber, K. 1972: Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor Fortschritte der Neurologie Psychiatrie und Ihrer Grenzgebiete 40(10): 564-568
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Glabb, J.; Hübner, W.; Glabb, S. 1973: Treatment of Parkinson's syndrome using L-dopa. 2 Zeitschrift für Arztliche Fortbildung 67(15): 745-753
Matussek, N.; Benkert, O.; Schneider, K.; Otten, H.; Pohlmeier, H. 1970: Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions Arzneimittel-Forschung 20(7): 934-935
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422
De Divitiis, E.; Cerillo, A.; Tata, M.R.; Decina, A. 1973: Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results Acta Neurologica 28(2): 208-212
Eisenlohr, J.J.; Gehlen, W. 1974: Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) Münchener Medizinische Wochenschrift 116(28): 1353-1356
Pimenta, A.d.M.; Friguglietti, D.J. 1971: Treatment of Parkinson's syndrome with L-dopa. in operated and nonoperated cases Revista Brasileira de Medicina 28(9): 481-496